Shuttle Pharmaceuticals Holdings, Inc.

NasdaqCM:SHPH Stock Report

Market Cap: US$2.1m

Shuttle Pharmaceuticals Holdings Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Chris Cooper

Chief executive officer

US$240.0k

Total compensation

CEO salary percentage80.65%
CEO tenure1.1yrs
CEO ownershipn/a
Management average tenure7.2yrs
Board average tenure5.7yrs

Recent management updates

Recent updates

Seeking Alpha • Sep 15

Shuttle Pharma awarded new patents for its radiation sensitizing technology platform

Newly public Shuttle Pharmaceuticals (NASDAQ:SHPH) on Thursday said it had been awarded patents in the U.S. and Hong Kong for its technology platform which reduces side effects for cancer patients treated with radiation therapy. The awarded patents were for SHPH's radiation sensitizing HDAC inhibitor technology platform, the company said in a statement. Histone deacetylase (HDAC) inhibitors are a class of drugs that target enzymes involved in the regulation of cellular functions that can inhibit cancer growth. The patents awarded were U.S. patent no. 11,407,723 and Hong Kong patent no. HK1250474, SHPH said, with European applications also under review. Shares of Shuttle Pharmaceuticals (SHPH) were 44.8% lower at $20.68 in mid-day trading, continuing their wild post-IPO ride. SHPH went public on Aug. 31, where it soared more than 300%, and has posted extreme swings in both negative and positive territories since then.

CEO Compensation Analysis

How has Chris Cooper's remuneration changed compared to Shuttle Pharmaceuticals Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$11m

Dec 31 2025US$240kUS$194k

-US$12m

Compensation vs Market: Chris's total compensation ($USD240.00K) is below average for companies of similar size in the US market ($USD652.98K).

Compensation vs Earnings: Insufficient data to compare Chris's compensation with company performance.

CEO

Chris Cooper (56 yo)

1.1yrs
Tenure
US$240,001
Compensation

Mr. Christopher Robert Cooper, also known as Chris, MBA, is CFO & Corporate Secretary of Arcus Development Group Inc. from April 09, 2026. He is CEO of Akanda Corp. from September 3, 2026. He is Independen...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Cooper
Interim Co-CEO & Directorno dataUS$240.00kno data
Milton Brown
Co-Founder13.8yrsUS$4.17kno data
Ryan Trasolini
Co-Chief Executive Officerless than a yearno datano data
Mira Jung
Co-Founder & Chief Scientific Officer for Biology13.8yrsno data0.093%
$ 1.9k
Yuying Liang
Chief Financial Officerless than a yearno datano data
Tyvin Rich
Chief Clinical Officer & Chief Medical Officerno dataUS$218.00k0.00017%
$ 3.5
Michael Vander Hoek
Vice President for Operations and Regulatoryno dataUS$548.47k0.0089%
$ 183.6
7.2yrs
Average Tenure
63.5yo
Average Age

Experienced Management: SHPH's management team is seasoned and experienced (7.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Cooper
Interim Co-CEO & Director1.1yrsUS$240.00kno data
Theodore Phillips
Chairman of Scientific Advisory Committee8.7yrsUS$93.70kno data
Ralph Weichselbaum
Member of Scientific Advisory Committee13.7yrsno datano data
J. Brown
Member of Scientific Advisory Committee9.7yrsno datano data
George Scorsis
Independent Chairman of the Board1.6yrsUS$226.83kno data
Joseph Armstrong
Member of Scientific Advisory Committee5.7yrsno datano data
Alejandro Villagra
Member of Scientific Advisory Committee9.7yrsno datano data
Angel Liriano
Independent Director1yrUS$7.57kno data
Adam Chambers
Director1yrUS$7.85kno data
5.7yrs
Average Tenure
50yo
Average Age

Experienced Board: SHPH's board of directors are considered experienced (5.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/14 22:30
End of Day Share Price 2026/09/14 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Shuttle Pharmaceuticals Holdings, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.